• Cell Therapeutics Inc., of Seattle, said the University of Washington has begun enrolling patients in a randomized Phase II trial testing tosedostat with either cytarabine or decitabine for elderly patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.